Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol

Richard Haynes, Colin Baigent, Paul Harden, Martin Landray, Murat Akyol, Argiris Asderakis, Alex Baxter, Sunil Bhandari, Paramit Chowdhury, Marc Clancy, Jonathan Emberson, Paul Gibbs, Abdul Hammad, Will Herrington, Kathy Jayne, Gareth Jones, Nithya Krishnan, Michael Lay, David Lewis, Iain Macdougall, Chidambaram Nathan, James Neuberger, Chas Newstead, Ravi Pararajasingam, Carmelo Puliatti, Keith Rigg, Peter Rowe, Adnan Sharif, Neil Sheerin, Sanjay Sinha, Chris Watson, Peter Friend, 3C Study Collaborative Group, Richard Haynes, Colin Baigent, Paul Harden, Martin Landray, Murat Akyol, Argiris Asderakis, Alex Baxter, Sunil Bhandari, Paramit Chowdhury, Marc Clancy, Jonathan Emberson, Paul Gibbs, Abdul Hammad, Will Herrington, Kathy Jayne, Gareth Jones, Nithya Krishnan, Michael Lay, David Lewis, Iain Macdougall, Chidambaram Nathan, James Neuberger, Chas Newstead, Ravi Pararajasingam, Carmelo Puliatti, Keith Rigg, Peter Rowe, Adnan Sharif, Neil Sheerin, Sanjay Sinha, Chris Watson, Peter Friend, 3C Study Collaborative Group

Abstract

Background: Kidney transplantation is the best treatment for patients with end-stage renal failure, but uncertainty remains about the best immunosuppression strategy. Long-term graft survival has not improved substantially, and one possible explanation is calcineurin inhibitor (CNI) nephrotoxicity. CNI exposure could be minimized by using more potent induction therapy or alternative maintenance therapy to remove CNIs completely. However, the safety and efficacy of such strategies are unknown.

Methods/design: The Campath, Calcineurin inhibitor reduction and Chronic allograft nephropathy (3C) Study is a multicentre, open-label, randomized controlled trial with 852 participants which is addressing two important questions in kidney transplantation. The first question is whether a Campath (alemtuzumab)-based induction therapy strategy is superior to basiliximab-based therapy, and the second is whether, from 6 months after transplantation, a sirolimus-based maintenance therapy strategy is superior to tacrolimus-based therapy. Recruitment is complete, and follow-up will continue for around 5 years post-transplant. The primary endpoint for the induction therapy comparison is biopsy-proven acute rejection by 6 months, and the primary endpoint for the maintenance therapy comparison is change in estimated glomerular filtration rate from baseline to 2 years after transplantation. The study is sponsored by the University of Oxford and endorsed by the British Transplantation Society, and 18 centers for adult kidney transplant are participating.

Discussion: Late graft failure is a major issue for kidney-transplant recipients. If our hypothesis that minimizing CNI exposure with Campath-based induction therapy and/or an elective conversion to sirolimus-based maintenance therapy can improve long-term graft function and survival is correct, then patients should experience better graft function for longer. A positive outcome could change clinical practice in kidney transplantation.

Trial registration: ClinicalTrials.gov, NCT01120028 and ISRCTN88894088.

Figures

Figure 1
Figure 1
Flowchart showing study treatments and randomizations, including proposed analyses.

References

    1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LYC, Held PJ, Port FK. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant 10.1056/NEJM199912023412303. N Eng J Med. 1999;341(23):1725–1730. doi: 10.1056/NEJM199912023412303.
    1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004;4(8):1289–1295. doi: 10.1111/j.1600-6143.2004.00515.x.
    1. Chapman JR, O’Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrology: JASN. 2005;16(10):3015–3026. doi: 10.1681/ASN.2005050463.
    1. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Eng J Med. 2003;349(24):2326–2333. doi: 10.1056/NEJMoa020009.
    1. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, Margreiter R, Hugo C, Grinyo JM, Frei U. Reduced exposure to calcineurin inhibitors in renal transplantation. N Eng J Med. 2007;357(25):2562–2575. doi: 10.1056/NEJMoa067411.
    1. Friend PJ, Rebello P, Oliveira D, Manna V, Cobbold SP, Hale G, Jamieson NV, Jamieson I, Calne RY, Harris DT. Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody. Transplant Proc. 1995;27(1):869–870.
    1. Huang E, Cho Y, Shah T, Peng A, Hayashi R, Bunnapradist S. Alemtuzumab induction in living donor kidney transplantation a multivariate analysis of the optn/ unos database. Transplantation. 2006;82(1 Suppl 2):375–376.
    1. Morgan RD, O’Callaghan JM, Knight SR, Morris PJ. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation. 2012;93(12):1179–1188. doi: 10.1097/TP.0b013e318257ad41.
    1. Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, Croy R, Holman J. Alemtuzumab induction in renal transplantation. N Eng J Med. 2011;364(20):1909–1919. doi: 10.1056/NEJMoa1009546.
    1. Flechner SM. Reviewing the evidence for de novo immunosuppression with sirolimus. Transplant Proc. 2008;40(10 Suppl):S25–S28.
    1. Schena FP, Pascoe MD, Alberu J, del Carmen RM, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87(2):233–242. doi: 10.1097/TP.0b013e3181927a41.
    1. Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, Moulin B, Frouget T, Le Meur Y, Glotz D. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant. 2009;9(5):1115–1123. doi: 10.1111/j.1600-6143.2009.02615.x.
    1. Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2011;377(9768):837–847. doi: 10.1016/S0140-6736(10)62318-5.
    1. Lebranchu Y, Thierry A, Thervet E, Buchler M, Etienne I, Westeel PF, de Ligny HB, Moulin B, Rerolle JP, Frouget T. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant. 2011;11(8):1665–1675. doi: 10.1111/j.1600-6143.2011.03637.x.
    1. Li Y, Zheng XX, Li XC, Zand MS, Strom TB. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation. 1998;66(10):1387–1388. doi: 10.1097/00007890-199811270-00021.
    1. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045. doi: 10.1146/annurev.iy.12.040194.005015.
    1. Kirk AD, Mannon RB, Kleiner DE, Swanson JS, Kampen RL, Cendales LK, Elster EA, Wakefield T, Chamberlain C, Hoffmann SC. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation. 2005;80(8):1051–1059. doi: 10.1097/01.tp.0000174341.49741.8f.
    1. Tan HP, Kaczorowski DJ, Basu A, Unruh M, McCauley J, Wu C, Donaldson J, Dvorchik I, Kayler L, Marcos A. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant. 2006;6(10):2409–2417. doi: 10.1111/j.1600-6143.2006.01495.x.
    1. Barth RN, Janus CA, Lillesand CA, Radke NA, Pirsch JD, Becker BN, Fernandez LA, Thomas Chin L, Becker YT, Odorico JS. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int. 2006;19(11):885–892. doi: 10.1111/j.1432-2277.2006.00388.x.
    1. Calne R, Moffatt SD, Friend PJ, Jamieson NV, Bradley JA, Hale G, Firth J, Bradley J, Smith KG, Waldmann H. Prope tolerance with induction using Campath 1H and low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients. Nippon Geka Gakkai Zasshi. 2000;101(3):301–306.
    1. Valmori D, Tosello V, Souleimanian NE, Godefroy E, Scotto L, Wang Y, Ayyoub M. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol. 2006;177(2):944–949.
    1. Wells AD, Li XC. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med. 1999;5:1303. doi: 10.1038/15260.
    1. Bloom DD, Hu H, Fechner JH, Knechtle SJ. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation. 2006;81(1):81–87. doi: 10.1097/01.tp.0000191940.13473.59.
    1. Gallon L, Gagliardini E, Benigni A, Kaufman D, Waheed A, Noris M, Remuzzi G. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H) Clin J Am Soc Nephrol. 2006;1(3):539–545. doi: 10.2215/CJN.01741105.
    1. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–470. doi: 10.7326/0003-4819-130-6-199903160-00002.
    1. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation. 2006;82(9):1153–1162. doi: 10.1097/01.tp.0000237101.58974.43.
    1. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335–371. doi: 10.1016/S0033-0620(85)80003-7.
    1. Matas AJ. Chronic progressive calcineurin nephrotoxicity: an overstated concept. Am J Transplant. 2011;11(4):687–692. doi: 10.1111/j.1600-6143.2011.03505.x.
    1. Chapman JR. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant. 2011;11(4):693–697. doi: 10.1111/j.1600-6143.2011.03504.x.
    1. Noris M, Casiraghi F, Todeschini M, Cravedi P, Cugini D, Monteferrante G, Aiello S, Cassis L, Gotti E, Gaspari F. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrology: JASN. 2007;18(3):1007–1018. doi: 10.1681/ASN.2006101143.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅